UNQ464 Inhibitors
The chemical class referred to as UNQ464 Inhibitors encompasses a diverse range of compounds targeting various cellular pathways. These inhibitors act through different mechanisms to interfere with the activation and function of the UNQ464 protein. Staurosporine and Wortmannin, for instance, disrupt UNQ464 by targeting its phosphorylation process. Staurosporine achieves this by binding to the ATP-binding site, preventing essential phosphorylation events. Wortmannin, a PI3K inhibitor, indirectly affects UNQ464 by disrupting PI3K-dependent pathways.
Inhibitors such as SB203580, U0126, and SB202190 specifically target MAPK pathways, hindering UNQ464 activation. LY294002 and GDC-0941, both PI3K inhibitors, negatively impact UNQ464 by disrupting PI3K-mediated signaling. Rapamycin, an mTOR inhibitor, modulates the mTOR pathway, indirectly influencing UNQ464 function. Additionally, PD98059, AG-490, and PP2 inhibit UNQ464 through interference with the MEK/ERK, JAK, and Src-dependent pathways, respectively.
This diverse array of inhibitors showcases the complexity of UNQ464 regulation, highlighting the interconnectedness of signaling pathways involved in its activation. The chemical class of UNQ464 Inhibitors offers a toolbox for investigating and manipulating UNQ464 function, providing researchers with valuable tools for exploring the intricacies of cellular signaling pathways and their role in UNQ464 activation and regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, can disrupt UNQ464 function by interfering with its phosphorylation. It binds to the ATP-binding site, preventing phosphorylation events essential for UNQ464 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a potent phosphoinositide 3-kinase (PI3K) inhibitor, may inhibit UNQ464 indirectly by disrupting PI3K-dependent signaling pathways. This disruption can lead to downstream effects that hinder UNQ464 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a specific p38 mitogen-activated protein kinase (MAPK) inhibitor, can hinder UNQ464 activity by blocking the p38 MAPK pathway. This inhibition disrupts the signaling cascade that UNQ464 participates in, leading to its functional suppression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, another PI3K inhibitor, can impede UNQ464 by targeting the PI3K pathway. Its interference with PI3K-mediated signaling can negatively impact UNQ464 activation, hindering its downstream effects. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, can potentially inhibit UNQ464 by disrupting the JNK signaling pathway. This interference can lead to a cascade of events that negatively impact UNQ464 activation and function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, a mitogen-activated protein kinase kinase (MEK) inhibitor, can interfere with UNQ464 by targeting the MEK/ERK pathway. Its inhibition of this pathway disrupts downstream events crucial for UNQ464 activation and functionality. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, can indirectly affect UNQ464 by modulating the mTOR pathway. The disruption of mTOR-mediated signaling can lead to downstream effects that impede UNQ464 function and activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a selective MEK inhibitor, can hinder UNQ464 by disrupting the MEK/ERK pathway. Its interference with this pathway prevents downstream events necessary for UNQ464 activation, leading to functional inhibition. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $86.00 $153.00 $275.00 $452.00 | 3 | |
SB202190, a specific p38 MAPK inhibitor, can inhibit UNQ464 by targeting the p38 MAPK pathway. Its disruption of this pathway interferes with downstream events crucial for UNQ464 activation and functional activity. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG-490, a Janus kinase (JAK) inhibitor, may potentially inhibit UNQ464 by disrupting JAK-mediated signaling pathways. This interference can lead to downstream effects that hinder UNQ464 activation and functionality. | ||||||